Back close

Amrita Centre for Nanosciences Scientists Developed Dual Drugs for Drug Resistant Leukemia

December 19, 2016 - 11:37
Amrita Centre for Nanosciences Scientists Developed Dual Drugs for Drug Resistant Leukemia

Scientists at Amrita Centre for Nanosciences and Molecular Medicine (ACNSMM), Amrita Vishwa Vidyapeetham, Kochi, developed a polymer protein, or protein-protein core-shell nano particle system, that takes one drug on the nano-shell and another one in the nano-core. This is the first cancer-nanomedicine patent for dual-drug core-shell technology issued to Indian researchers.

This edible work at the center had proved that when two drugs can be simultaneously delivered in this fashion there was the potential for a substantial remission of drug resistant leukemia for which there are no other treatments currently available.  

Department of Biotechnology, Government of India, selected this product as their first nanomedicine product for translation development to the clinic and has funded translational research up to Phase I trials. The scientists feel this may be India’s first dual-drug cancer nanomedicine that will hit the clinical trials soon.

This drug delivery system for cancer received the US patent (Publication number US20150342896/2016) and related work was published in Nanomedicine: NBM (Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine).

Admissions Apply Now